Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden

Thromb Haemost. 2009 Feb;101(2):405-7.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Blood Coagulation / drug effects
  • Blood Coagulation / genetics
  • Blood Component Transfusion
  • Child
  • Enoxaparin / therapeutic use
  • Factor V / genetics*
  • Humans
  • Male
  • Mutation*
  • Protein C / therapeutic use*
  • Protein C Deficiency / blood
  • Protein C Deficiency / drug therapy*
  • Protein C Deficiency / genetics
  • Prothrombin / genetics*
  • Purpura Fulminans / drug therapy*
  • Purpura Fulminans / genetics
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome
  • Warfarin / adverse effects
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Enoxaparin
  • Protein C
  • Recombinant Proteins
  • factor V Leiden
  • Warfarin
  • Factor V
  • Prothrombin
  • drotrecogin alfa activated